Law Office Of Jonathan M. Stein, P.L. Investigates Possible Breaches Of Fiduciary Duty By The Officers And Directors Of Acura Pharmaceuticals, Inc.
The Law Office of Jonathan M. Stein, P.L. is investigating the officers and directors of Acura Pharmaceuticals, Inc. ("Acura" or the "Company") (Nasdaq:ACUR) for possible breaches of fiduciary duty and other violations of state and federal law. On September 10, 2010, a class action lawsuit was filed in the U.S. District Court for the Northern District of Illinois alleging that certain officers and directors of the Company violated the Securities Exchange Act of 1934 by concealing material adverse facts about the Company’s product Acurox, a drug containing oxycodone with a niacin additive.
The investigation involves whether the officers and directors of Acura breached their fiduciary duties to Acura stockholders by failing to disclose the truth about the effectiveness of Acurox and its proprietary “Aversion Technology” that supposedly provides abuse deterrent qualities to orally-administered drugs, such as Acurox. Specifically, on April 20, 2010, the FDA indicated that Acura's Aversion Technology was nowhere near effective enough to warrant approval, that the Company's clinical data was defective, that its clinical studies were not properly designed, that the Company had wholly ignored specific directives from FDA over the past four years as to specific clinical trials and evidence Acura had to demonstrate, and that no evidence had ever been presented to the FDA that the niacin additive discouraged abusers from abusing oxycodone.
If you currently own stock in Acura and wish to discuss your rights as a shareholder, or if you have information regarding the above investigation, please contact Jonathan M. Stein, Esq. either via email at jstein@jonathansteinlaw.com or by telephone at (561) 961-2244.
The Law Office of Jonathan M. Stein, P.L. represents shareholders and
consumers in complex litigation, including class action and derivative
litigation. More information about the firm is available through its
website,
www.jonathansteinlaw.com,
and upon request from the firm. Jonathan M. Stein is the attorney
responsible for the content of this release.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
